fridays glp 1 latest Health Review: GLP-1, Nutrition, Mental Health & Fitness in One App @joinfridays , Getting started on

Diabetes 58:23762385

Ter Arkh

The update reinforces that: Residual risk persists despite statin therapy Elevated triglycerides contribute to ongoing CV risk Evidence-based therapies like icosapent ethyl can help reduce CV events when added to statins in high-risk patients To view or add a comment, sign in My Publishing in Iternational Magazine Effectiveness of SGLT2 Inhibitors in Reducing Cardiovascular Risk in Non-Diabetic Patients with Underlying Coronary Heart Disease Result : The main composite outcome occurred in 6 cases (15.0%) in the SGLT2 inhibitor group in comparison to 14 patients (35.0%) in the control cohort (p = 0.041)

Weight regain during the one-year post-treatment phase was 6 kg larger for participants who had previously received liraglutide alone than participants who had previously received supervised exercise alone, despite similar initial weight loss

It is also one of the strongest arguments for the combination approach, where sermorelin helps build the metabolic foundation (lean muscle mass, improved hormonal milieu) that makes weight maintenance possible even after semaglutide is discontinued

They are typically administered intramuscularly (into the muscle)